spacer
home > ict > autumn 2016 > does size really matter?
PUBLICATIONS
International Clinical Trials

Does Size Really Matter?

Over the past few years, outsourcing clinical trials has become an attractive option for sponsored pharmaceutical research. Therapeutic expertise, resource management, technological advantages and cost cutting are some of the primary reasons for any biopharmaceutical sponsor to outsource clinical trials. This has led to tremendous growth in the size and number of CROs in the past two decades. Most of them position themselves as a fullservice CRO in the drug development market, although – based on study-specific requirements – the majority of them are ready to sub-source for their functional needs.

Collaborating with a CRO is now an essential and significant step for sponsors during the clinical development process. The dynamic shift in outsourcing methodology and service fragmentation has left them with critical decisions to be taken at the juncture of CRO sourcing. There are variable sizes of companies on both the sponsor and the CRO side, and the principle of ‘one size fits all’ is not pragmatic from an operability perspective.

Different Options


Full-service and functional outsourcing remain as two distinct but basic models of collaboration. Traditionally, per-study outsourcing has been followed until recently, when strategic partnerships between Big Pharma and sizeable CROs began gaining popularity.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mohamed El Malt, MD, PhD, is Chief Medical Consultant at Europital. In addition to 15 years of working as a general and oncology surgeon, Mohamed has more than 32 years of experience as a medical doctor, 18 of which he spent in clinical research and drug development at academic medical centres, as well as in pharma companies and CROs as an investigator, project leader and medical director.
spacer
Mohamed El Malt
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Smart Bioprocessing with the new Eppendorf Control System

Hamburg, February 12, 2020 Working with flexible systems that evolve with the changing needs in a lab is indispensable. With the SciVario twin, Eppendorf, a key life science company, introduces its latest bioreactor control system for small- and bench-scale applications. The intelligent controller and new, innovative bay-drawer system enables the exchange of standardized modules to flexibly adapt the controller to the changing requirements in a laboratory.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement